Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:60075
Name estrogen-receptor positive breast cancer
Definition A breast cancer that is characterized by the presence of estrogen receptors.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer estrogen-receptor positive breast cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 amp Dovitinib estrogen-receptor positive breast cancer sensitive detail...
FGFR1 amp Cediranib estrogen-receptor positive breast cancer sensitive detail...
FGFR1 amp Nintedanib estrogen-receptor positive breast cancer sensitive detail...
FGFR1 amp Brivanib estrogen-receptor positive breast cancer no benefit detail...
PIK3CA E545K AZD8835 estrogen-receptor positive breast cancer sensitive detail...
PIK3CA K111N AZD8835 estrogen-receptor positive breast cancer sensitive detail...
PIK3CA mutant AZD8835 estrogen-receptor positive breast cancer sensitive detail...
PIK3CA mutant Fulvestrant + Pictilisib estrogen-receptor positive breast cancer no benefit detail...
PIK3CA mutant Fulvestrant estrogen-receptor positive breast cancer no benefit detail...
PIK3CA act mut Capivasertib + Tamoxifen estrogen-receptor positive breast cancer predicted - sensitive detail...
PTEN inact mut Pictilisib estrogen-receptor positive breast cancer sensitive detail...
PTEN inact mut Fulvestrant + Pictilisib estrogen-receptor positive breast cancer sensitive detail...
MST1R pos PIK3CA H1047R Buparlisib estrogen-receptor positive breast cancer predicted - sensitive detail...
MST1R pos PIK3CA H1047R BMS-777607 estrogen-receptor positive breast cancer predicted - sensitive detail...
MST1R pos PIK3CA H1047R BMS-777607 + Buparlisib estrogen-receptor positive breast cancer predicted - sensitive detail...
MST1R pos PIK3CA wild-type BMS-777607 + Buparlisib estrogen-receptor positive breast cancer predicted - sensitive detail...
MST1R pos PIK3CA wild-type Buparlisib estrogen-receptor positive breast cancer predicted - sensitive detail...
MST1R pos PIK3CA wild-type BMS-777607 estrogen-receptor positive breast cancer predicted - sensitive detail...
FGFR1 amp E7090 estrogen-receptor positive breast cancer sensitive detail...
PIK3CA E78K PIK3CA E726K PIK3CA D939G Alpelisib + Letrozole estrogen-receptor positive breast cancer no benefit detail...
FGFR1 amp Alpelisib estrogen-receptor positive breast cancer resistant detail...
FGFR1 amp Lucitanib estrogen-receptor positive breast cancer sensitive detail...
FGFR1 over exp PIK3CA mut Alpelisib + Lucitanib estrogen-receptor positive breast cancer sensitive detail...
RB1 loss Palbociclib estrogen-receptor positive breast cancer resistant detail...
PIK3CA P447_L455del Alpelisib + Letrozole estrogen-receptor positive breast cancer predicted - sensitive detail...
PIK3CA mutant Letrozole estrogen-receptor positive breast cancer predicted - sensitive detail...
ERBB3 T355I Fulvestrant + Lapatinib estrogen-receptor positive breast cancer sensitive detail...
ERBB3 T355I Lapatinib estrogen-receptor positive breast cancer no benefit detail...
ERBB3 T355I SCH772984 estrogen-receptor positive breast cancer no benefit detail...
ERBB3 T355I Lapatinib + SCH772984 estrogen-receptor positive breast cancer no benefit detail...
ERBB3 T355I Fulvestrant estrogen-receptor positive breast cancer no benefit detail...
RB1 mutant Palbociclib estrogen-receptor positive breast cancer predicted - resistant detail...
TP53 wild-type KRT-232 estrogen-receptor positive breast cancer predicted - sensitive detail...
PIK3CA H1047R Everolimus estrogen-receptor positive breast cancer predicted - sensitive detail...
PIK3CA act mut Palbociclib + Taselisib estrogen-receptor positive breast cancer predicted - sensitive detail...
FGFR1 W4C FGFR1 amp Lucitanib estrogen-receptor positive breast cancer predicted - sensitive detail...
ATM LOH ATM inact mut Ceralasertib + Olaparib estrogen-receptor positive breast cancer predicted - sensitive detail...
FGFR1 W4C FGFR1 amp Rogaratinib estrogen-receptor positive breast cancer no benefit detail...
FGFR2 M538I AZD4547 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 N550K AZD4547 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 K660N AZD4547 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 M538I FIIN-2 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 N550K FIIN-2 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 K660N FIIN-2 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 M538I FIIN-3 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 N550K FIIN-3 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 K660N FIIN-3 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 M538I Trametinib estrogen-receptor positive breast cancer sensitive detail...
FGFR2 N550K Trametinib estrogen-receptor positive breast cancer sensitive detail...
FGFR2 K660N Trametinib estrogen-receptor positive breast cancer sensitive detail...
FGFR2 M538I SHP099 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 N550K SHP099 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 K660N SHP099 estrogen-receptor positive breast cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00570323 Phase II Anastrozole + Fulvestrant Anastrozole Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer Completed USA 0
NCT00759642 Phase II Lapatinib Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy Terminated USA 0
NCT01027416 Phase I Tamoxifen Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients Completed USA 0
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed USA | FRA | ESP 1
NCT01219699 Phase I Alpelisib Alpelisib + Fulvestrant A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene Completed USA | ESP | DEU 2
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed USA | FRA | ESP 4
NCT01594216 Phase II Exemestane + Ruxolitinib Ruxolitinib in Estrogen Receptor Positive Breast Cancer Completed USA 0
NCT01857193 Phase Ib/II Everolimus + Exemestane + Ribociclib Exemestane + Ribociclib Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Completed USA | FRA | ESP | BEL 1
NCT01872260 Phase I Alpelisib + Letrozole Alpelisib + Letrozole + Ribociclib Letrozole + Ribociclib Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Active, not recruiting USA | ITA | FRA | ESP 4
NCT01990209 Phase II Orteronel Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Completed USA 0
NCT02035813 Phase II Ribociclib Eribulin DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). Active, not recruiting DEU 0
NCT02049957 Phase Ib/II Fulvestrant + Sapanisertib Exemestane + Sapanisertib Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer Completed USA | FRA | BEL 0
NCT02115282 Phase III Exemestane + Goserelin Entinostat + Exemestane + Goserelin Entinostat in Patients With Recurrent Advanced Hormone Receptor-Positive Breast Cancer Active, not recruiting USA 1
NCT02219789 Phase I Fulvestrant Alisertib Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Completed USA 0
NCT02229084 Phase Ib/II Montanide ISA 51 + P10s-PADRE P10s-PADRE Vaccination of High Risk Breast Cancer Patients Recruiting USA 0
NCT02308020 Phase II Abemaciclib A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain Completed USA | ITA | FRA | ESP | CAN | BEL | AUT 2
NCT02340221 Phase III Fulvestrant + Taselisib Fulvestrant A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER) Terminated USA | ITA | FRA | ESP | DEU | CAN | AUT 21
NCT02395627 Phase II Pembrolizumab + Tamoxifen + Vorinostat Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification Terminated USA 0
NCT02569801 Phase II GDC-0810 Fulvestrant A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy Terminated USA | ESP | DEU 3
NCT02580448 Phase Ib/II Seviteronel A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer Completed USA 0
NCT02598557 Phase II Exemestane Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer Active, not recruiting USA | ITA 0
NCT02599714 Phase Ib/II Fulvestrant + Palbociclib + Vistusertib Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR) Active, not recruiting USA 1
NCT02676986 Phase II Enzalutamide + Exemestane Exemestane Enzalutamide Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB) Unknown status USA | ESP | DEU 2
NCT02734615 Phase I Alpelisib + LSZ 102 LSZ 102 + Ribociclib LSZ 102 Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers Terminated USA | ITA | FRA | DEU | BEL 2
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Active, not recruiting USA | FRA | CAN 1
NCT02820961 Phase I Entinostat + Exemestane Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer Completed USA 0
NCT02913430 Phase II Fulvestrant + Palbociclib Palbociclib + Tamoxifen Phase II Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib Active, not recruiting USA 0
NCT02918084 Phase III Exemestane Anastrozole Letrozole CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer (GIM10-CONSENT) Active, not recruiting ITA 0
NCT02988986 Phase II Sapanisertib + Tamoxifen TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer Completed USA 0
NCT03092635 Phase I Metformin + OPC AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy Terminated USA 0
NCT03201913 Phase I TTC-352 Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy Completed USA 0
NCT03285412 Phase II Ribociclib CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer Recruiting USA 0
NCT03289039 Phase II Neratinib Fulvestrant + Neratinib Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer Active, not recruiting USA 0
NCT03321981 Phase II Letrozole + Zenocutuzumab Anastrozole + Zenocutuzumab Fulvestrant + Zenocutuzumab Exemestane + Zenocutuzumab Trastuzumab + Zenocutuzumab Trastuzumab + Vinorelbine + Zenocutuzumab MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer Active, not recruiting USA | FRA | ESP | BEL 3
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Active, not recruiting USA | CAN | BEL 6
NCT03361800 Phase I Entinostat Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC Terminated USA 0
NCT03573648 Phase II Leuprolide Avelumab + Palbociclib + Tamoxifen Avelumab + Tamoxifen Leuprolide + Palbociclib Avelumab + Leuprolide Avelumab + Leuprolide + Palbociclib Tamoxifen Goserelin Palbociclib + Tamoxifen Avelumab + Goserelin Goserelin + Palbociclib Avelumab + Goserelin + Palbociclib Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer Recruiting USA 0
NCT03584009 Phase II Fulvestrant Fulvestrant + Venetoclax A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy Terminated USA | DEU | CAN 2
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Recruiting USA | FRA | ESP 3
NCT03874325 Phase II Durvalumab + Exemestane Durvalumab + Letrozole Anastrozole + Durvalumab Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer Terminated USA 0
NCT03900884 Phase I Letrozole + Palbociclib + Venetoclax Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer (PALVEN) Recruiting 1
NCT04054752 Phase I NT-I7 Vaccine Response With NT-I7 Recruiting USA 0
NCT04109066 Phase III Paclitaxel Anthracycline + Cyclophosphamide + Nivolumab Nivolumab + Paclitaxel Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer (CheckMate 7FL) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 24
NCT04190056 Phase II Pembrolizumab + Tamoxifen Pembrolizumab + Tamoxifen + Vorinostat Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer Recruiting USA 0
NCT04197999 Phase I GMI-1359 A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer Terminated USA 0
NCT04256941 Phase II Abemaciclib + Fulvestrant Fulvestrant + Palbociclib Letrozole + Palbociclib Fulvestrant + Ribociclib Abemaciclib + Letrozole Anastrozole + Palbociclib Anastrozole + Ribociclib Letrozole + Ribociclib Abemaciclib + Anastrozole Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study Recruiting USA 0
NCT04305834 Phase II Abemaciclib Abemaciclib Monotherapy in Treating Older Patients With Hormone Receptor Positive Metastatic Breast Cancer Recruiting USA 0
NCT04478279 Phase Ib/II ST-101 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT04557449 Phase I Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4) Recruiting USA 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04789668 Phase Ib/II M7824 + Pimasertib Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases Active, not recruiting USA 0
NCT04802759 Phase Ib/II Abemaciclib + Giredestrant Giredestrant + Ipatasertib Giredestrant Everolimus + Giredestrant GDC-0077 + Giredestrant Giredestrant + Ribociclib A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer Recruiting USA | ESP 3
NCT05020860 Phase II Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome in Patients With Early Stage Breast Cancer (RESPONSE) Not yet recruiting USA 0